Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer.

Trial Profile

Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Ixabepilone (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 26 Jun 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Planned end date changed from 1 Nov 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top